Proactive Investors - Run By Investors For Investors

Shares of Savara plunge after disappointing Phase 3 lung disease study results

Patients given the treatment saw an improvement not statistically significant from the placebo
Savara is an Austin, Texas orphan lung disease pharmaceutical company

Savara Inc (NASDAQ:SVRA) stock plummeted after a Phase 3 trial of its treatment for an autoimmune lung disease failed to reach the desired results.

Molgradex, the company’s drug for Autoimmune Alveolar Pulmonary Proteinosis, was tested against a placebo and measured for improvement in the alveolar-arterial oxygen gradient, the ratio of oxygen concentration in the lungs and arteries.

Shares collapsed on the disappointing results, falling 75% to $2.59.

READ: Hemispherx treats first patient with cancer drug Ampligen in Phase 2 clinical trials

Patients given the treatment saw an improvement not statistically significant from the placebo.

That said, patient-reported outcomes and quality of life measurements did improve with treatment, which was considered a secondary endpoint of the study, known as IMPALA.

"Disappointingly, with the placebo effect stronger than anticipated, the study did not meet its primary endpoint,” CEO Rob Neville said. “We are preparing to meet with the FDA and [the European Medicines Agency] to discuss the results from this study and to determine our options to seek approval based on the current data, and potentially conduct an additional study incorporating the learnings from IMPALA."

Savara is an Austin, Texas orphan lung disease pharmaceutical company. 

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

View full SVRA profile View Profile

Savara Timeline

Related Articles

A stomach adenocarcinoma
February 12 2019
The company’s B-cell peptide cancer vaccines have shown promise in pre-clinical and early-stage study.
woman's face
Here we take a closer look at SkinBioTherapeutics, the life sciences group that is using bacteria to improve people’s skin
consumer health segment overview
January 10 2019
The company sells clinically validated anti-ageing products for hair, skin and body.
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use